Clinical Trials Sponsored by Novartis Pharmaceuticals

Total 21612 results

Novartis Pharmaceuticals

Completed

A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients

Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients

Austria, Switzerland
Novartis Pharmaceuticals

Terminated

To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)

Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

Austria, Australia
Novartis Pharmaceuticals

Terminated

Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients (VARIABLE)

Type 2 Diabetes Mellitus
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine

Essential Hypertension

Taiwan, Japan, Philippines, China, Korea, Republic of, Malaysia
Novartis Pharmaceuticals

Completed

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Mild and Moderate Renal Impairment

Russian Federation, Germany, Serbia
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Nevoid Basal Cell Carcinoma Syndrome | Basal Cell Carcinoma | Gorlin Syndrome

Belgium, Austria, Germany, Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

Essential Hypertension

Japan
Novartis Pharmaceuticals

Completed

Phase III Study in Refractory Behcet's Disease (SHIELD)

Behcet Disease

India, Turkey, Spain, Germany, Italy, France, Israel, Greece, Korea, Republic of, Hong Kong, United States, Egypt, Jordan, Singapore, Switzerland, Taiwan, Tunisia
Novartis Pharmaceuticals

Terminated

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) (IMPRES Extn)

Pulmonary Arterial Hypertension

Spain, Germany, Belgium, Switzerland, United States, Netherlands, Austria, Canada, Korea, Republic of, Italy, Japan, United Kingdom, France
Novartis Pharmaceuticals

Completed

Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction

Hypertension With Renal Dysfunction

Japan
Novartis Pharmaceuticals

Completed

A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

Hepatic Impairment

Germany
Novartis Pharmaceuticals

Terminated

Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Germany, Belgium, United Kingdom, United States, Lithuania, Italy, Australia
Novartis Pharmaceuticals

Completed

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Egypt, Hungary, France, Guatemala, Panama, Slovakia, Slovenia
Novartis Pharmaceuticals

Completed

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

Diabetes Mellitus, Type 2 | Atherosclerosis | Prediabetic State

Germany, Israel, United States, Canada, United Kingdom
Novartis Pharmaceuticals

Completed

Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change (EPOC)

Relapsing Remitting Multiple Sclerosis

Italy
Novartis Pharmaceuticals

Completed

SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance (SCHEDULE)

Renal Function and Chronic Allograft Vasculopathy

Norway, Denmark, Sweden
Novartis Pharmaceuticals

Completed

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma (QAB149)

Asthma

United States
Novartis Pharmaceuticals

Completed

Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea (LARCID)

Chemotherapy-induced Diarrhea

Brazil
Novartis Pharmaceuticals

Completed

A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)

Non-Small-Cell Lung Cancer

Greece, Taiwan, Germany, Belgium, Italy, Spain, United Kingdom, Korea, Republic of, Netherlands, China, Hungary, Poland, France, Thailand, Portugal
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma

Asthma

Germany, Slovakia, Poland, Belgium, Estonia, Hungary, Latvia, Lithuania, Turkey, Canada, India, Netherlands, Ukraine, Russian Federation, Malaysia, Japan, Thailand
Novartis Pharmaceuticals

Completed

Safety and Tolerability of BVS857 in Subjects With Insulin Resistance

Insulin Resistance

United States
Novartis Pharmaceuticals

Completed

A Global Imatinib and Nilotinib Pregnancy Exposure Registry

All Indications for Glivec/Gleevec and Tasigna

United States
Novartis Pharmaceuticals

Completed

A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis

Plaque Psoriasis
Novartis Pharmaceuticals

Completed

A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer (PHOENIX I)

Locally Advanced Cervical Cancer

Brazil
Novartis Pharmaceuticals

Withdrawn

Trial of Telbivudine Combination Therapy vs. Continued Adefovir Monotherapy

Chronic Hepatitis B
Novartis Pharmaceuticals

Completed

Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®

Hypocalcemia | Paget's Disease of the Bone

United States
Novartis Pharmaceuticals

Completed

NVA237 Versus Placebo 12-week Efficacy Study

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy

Liver Transplantation

Germany, Netherlands, Switzerland, Austria
Novartis Pharmaceuticals

Completed

ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients

Renal Transplantation

Switzerland
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease

Germany, Austria, France
Novartis Pharmaceuticals

Completed

A Phase I Study of LFA102 in Japanese Patients

Castration-resistant Prostate Cancer, Advanced Breast Cancer

Japan
Novartis Pharmaceuticals

Completed

Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment (RELIGHT)

Diabetic Retinopathy | Macular Oedema

United Kingdom
Novartis Pharmaceuticals

Terminated

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression (REGAIN)

Depression | Relapsing-remitting Multiple Sclerosis

Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients

Chronic Renal Failure

Israel
Novartis Pharmaceuticals

Completed

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (EPOC)

Relapsing Remitting Multiple Sclerosis

Russian Federation
Novartis Pharmaceuticals

Completed

Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study) (IDEALE)

Renal Transplantation

France
Novartis Pharmaceuticals

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program (Senator)

Renal Transplantation

Germany
Novartis Pharmaceuticals

Completed

Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients (MACS1295)

First or Second Line HER2-negative Breast Cancer | Metastatic Disease Without Bone Metastasis

United States
Novartis Pharmaceuticals

Completed

Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (GLOW5)

Chronic Obstructive Pulmonary Disease

Germany, India, South Africa, Croatia, Estonia, Poland, Lithuania, Guatemala, Czech Republic, France, Philippines, Korea, Republic of, Taiwan, Canada, Latvia
Novartis Pharmaceuticals

Completed

Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes

Type 2 Diabetes Mellitus

China
Novartis Pharmaceuticals

Completed

Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients (CERTITEM)

Renal Interstitial Fibrosis

France
Novartis Pharmaceuticals

Completed

A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)

Hepatitis B, Chronic

Argentina, Brazil, Germany, Thailand
Novartis Pharmaceuticals

Completed

Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BEACON)

Chronic Obstructive Pulmonary Disease

Netherlands, Austria, Denmark, Norway, Sweden
Novartis Pharmaceuticals

Terminated

Human Urine Sample Collection for Alport Nephropathy Biomarker Studies

Alport Syndrome
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Pathological Myopia

Germany, India, Japan, Turkey, Austria, Switzerland, Italy, Lithuania, Hungary, France, Slovakia, United Kingdom, Korea, Republic of, Portugal, Hong Kong, Canada, Singapore, Spain, Latvia, Poland
Novartis Pharmaceuticals

Completed

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis (EPOC)

Relapsing Forms of Multiple Sclerosis

United States, Canada, Puerto Rico
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Acute Gouty Arthritis

Hungary, Germany, United States, Lithuania, Canada
Novartis Pharmaceuticals

Completed

The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (BLAZE)

Chronic Obstructive Pulmonary Disease

Germany, Belgium, Spain, Canada, United Kingdom
Novartis Pharmaceuticals

Withdrawn

Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis (SUPPORT)

Uveitis
Novartis Pharmaceuticals

Withdrawn

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Chronic Obstructive Pulmonary Disease

Germany, Austria

3

Subscribe